EGFR and non-small cell lung carcinoma: In advanced NSCLC patients carrying sensitized epidermal growth factor receptor (EGFR) mutations, the use of EGFR-tyrosine kinase inhibitors (TKIs) in combination with targeted therapy drugs is considered a viable treatment option, but can result in the eventual development of EGFR-TKI resistance in patients.